JGC
ITCI

J. Goldman & Co’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

J. Goldman & Co’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-175,500
Closed -$12.6M – 546
2023
Q4 		$12.6M Buy
+175,500
New +$10.1M 0.51% 66
2023
Q3 		– Sell
-45,900
Closed -$2.91M – 514
2023
Q2 		$2.91M Buy
+45,900
New +$2.86M 0.11% 180
2022
Q1 		– Sell
-47,300
Closed -$2.48M – 468
2021
Q4 		$2.48M Buy
+47,300
New +$1.99M 0.14% 177
2021
Q1 		– Sell
-66,800
Closed -$2.12M – 549
2020
Q4 		$2.12M Buy
+66,800
New +$1.76M 0.11% 189
2020
Q3 		– Sell
-112,500
Closed -$2.89M – 406
2020
Q2 		$2.89M Buy
+112,500
New +$2.28M 0.18% 134
2019
Q3 		– Sell
-40,000
Closed -$519K – 378
2019
Q2 		$519K Sell
40,000
-64,000
-62% -$821K 0.04% 218
2019
Q1 		$1.27M Buy
+104,000
New +$1.33M 0.07% 186
2018
Q1 		– Sell
-182,600
Closed -$2.64M – 453
2017
Q4 		$2.64M Buy
182,600
+52,600
+40% +$812K 0.14% 173
2017
Q3 		$2.05M Buy
+130,000
New +$1.91M 0.1% 193

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

J. Goldman & Co's ITCI Position: Q1 2024 in Review

J. Goldman & Co sold out of Intra-Cellular Therapies Inc. (ITCI) in Q1 2024, closing a stake of 106,080 shares — an estimated $7.6M sold.

J. Goldman & Co first reported a position in ITCI in Q3 2016 and held it in 11 quarters. The position peaked at $7.6M in Q4 2023. 346 funds tracked by Wall St. Rank hold ITCI as of Q1 2024.

  • J. Goldman & Co reported no remaining Intra-Cellular Therapies Inc. position as of Q1 2024 after selling out during the quarter.
  • J. Goldman & Co sold 106,080 Intra-Cellular Therapies Inc. shares in Q1 2024, an estimated $7.6M.
  • J. Goldman & Co first reported a position in Intra-Cellular Therapies Inc. in Q3 2016 and held it in 11 quarters.
  • J. Goldman & Co's Intra-Cellular Therapies Inc. position peaked at $7.6M in Q4 2023.
  • 346 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2024.

Based on J. Goldman & Co's 13F filing for Q1 2024, filed 15 May 2024.